No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRx-Reference-Cited by-同舟云学术

No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRx

Published:2022-12-20 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Roe Sophie A.^ORCID,DeSalve Dayna S.^ORCID,Piper Brian J.^ORCID

Abstract

AbstractObjectiveThe purpose of this report was to analyze black market diversions of atomoxetine, a non-stimulant medication for ADHD, submitted to StreetRx.MethodData related to black market atomoxetine purchases entered on StreetRx between 2015 and 2019 were analyzed. Data included generic drug name, dosage, purchase price, and date and location in the United States. The mean price per milligram was determined and a heatmap generated.ResultsThe average price per milligram cost of 113 diverted atomoxetine submissions was $1.35 (± $2.76 SD) (Median = $0.05, Min = $0.01, Max = $20.00). The states with the most submissions included Michigan (11), Pennsylvania (9), Indiana (8), and Ohio (8).ConclusionFurture qualitative studies should investigate reasons why individuals are motivated to purchase atomoxetine, a non-stimulant medication, on the black market (recreational vs. nootropic vs. other clinical uses).

Publisher

Cold Spring Harbor Laboratory

Reference43 articles.

1. About StreetRx – latest street prices for illicit and prescription drugs. (n.d.). StreetRx. Retrieved November 29, 2022, from https://streetrx.com/about.php.

2. Atomoxetine. GoodRx. https://www.goodrx.com/atomoxetine?utm_campaign=11825625966&utm_content=132555354658&utm_source=google&utm_medium=cpc&utm_term=dsa-1548565242935&gclid=CjwKCAjwrNmWBhA4EiwAHbjEQLICDTFGTrOz24-WxOA0_7gfuWsqUJaTfscMN67G2evrcPwsGCFTbRoCIikQAvD_BwE&gclsrc=aw.ds&form=capsule&dosage=40mg&quantity=30&label_override=atomoxetine.

3. Heatmapper: web-enabled heat mapping for all

4. Brasch, K. , Smith, L. , Roe, S. , Groff, E. , DeSalve, D. , McCall, K. , Nichols, S. , & Piper, B. (in preparation). Examination of diversion of ADHD pharmacotherapies with StreetRx.

5. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners